184 related articles for article (PubMed ID: 34624732)
1. Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania.
Mohamed Z; Scott N; Nayagam S; Rwegasha J; Mbwambo J; Thursz MR; Brown AS; Hellard M; Lemoine M
Int J Drug Policy; 2022 Jan; 99():103458. PubMed ID: 34624732
[TBL] [Abstract][Full Text] [Related]
2. Upscaling prevention, testing and treatment to control hepatitis C as a public health threat in Dar es Salaam, Tanzania: A cost-effectiveness model.
Scott N; Mohamed Z; Rwegasha J; Mbwambo J; Lemoine M; Hellard M
Int J Drug Policy; 2021 Feb; 88():102634. PubMed ID: 31882272
[TBL] [Abstract][Full Text] [Related]
3. An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis.
Mafirakureva N; Stone J; Fraser H; Nzomukunda Y; Maina A; Thiong'o AW; Kizito KW; Mucara EWK; González Diaz CI; Musyoki H; Mundia B; Cherutich P; Nyakowa M; Lizcano J; Chhun N; Kurth A; Akiyama MJ; Waruiru W; Bhattacharjee P; Cleland C; Donchuk D; Luhmann N; Loarec A; Maman D; Walker J; Vickerman P
Addiction; 2022 Feb; 117(2):411-424. PubMed ID: 34184794
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial.
Lim AG; Aas CF; Çağlar ES; Vold JH; Fadnes LT; Vickerman P; Johansson KA
Addiction; 2023 Dec; 118(12):2424-2439. PubMed ID: 37515462
[TBL] [Abstract][Full Text] [Related]
5. Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania.
Fraser H; Stone J; Wisse E; Sambu V; Mfisi P; Duran IJ; Soriano MA; Walker JG; Makere N; Luhmann N; Kafura W; Nouvellet M; Ragi A; Mundia B; Vickerman P
J Int AIDS Soc; 2021 Oct; 24(10):e25817. PubMed ID: 34661964
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico.
Marquez LK; Fleiz C; Burgos JL; Cepeda JA; McIntosh C; Garfein RS; Kiene SM; Brodine S; Strathdee SA; Martin NK
Addiction; 2021 Oct; 116(10):2734-2745. PubMed ID: 33620750
[TBL] [Abstract][Full Text] [Related]
7. The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania.
Mohamed Z; Rwegasha J; Kim JU; Shimakawa Y; Poiteau L; Chevaliez S; Bhagani S; Taylor-Robinson SD; Thursz MR; Mbwambo J; Lemoine M
J Viral Hepat; 2018 Dec; 25(12):1438-1445. PubMed ID: 29974582
[TBL] [Abstract][Full Text] [Related]
8. Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis.
Girardin F; Hearmon N; Negro F; Eddowes L; Bruggmann P; Castro E
J Viral Hepat; 2019 Feb; 26(2):236-245. PubMed ID: 30338887
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England.
Ward Z; Reynolds R; Campbell L; Martin NK; Harrison G; Irving W; Hickman M; Vickerman P
Addiction; 2020 Aug; 115(8):1509-1521. PubMed ID: 31984606
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania.
Lambdin BH; Lorvick J; Mbwambo JK; Rwegasha J; Hassan S; Lum P; Kral AH
Int J Drug Policy; 2017 Jul; 45():64-69. PubMed ID: 28628854
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
Scott N; Iser DM; Thompson AJ; Doyle JS; Hellard ME
J Gastroenterol Hepatol; 2016 Apr; 31(4):872-82. PubMed ID: 26514998
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population.
Stevens ER; Nucifora KA; Hagan H; Jordan AE; Uyei J; Khan B; Dombrowski K; des Jarlais D; Braithwaite RS
Clin Infect Dis; 2020 Jun; 70(12):2652-2662. PubMed ID: 31400755
[TBL] [Abstract][Full Text] [Related]
16. Modelling the impact and cost-effectiveness of non-governmental organizations on HIV and HCV transmission among people who inject drugs in Ukraine.
Stone J; Trickey A; Walker JG; Bivegete S; Semchuk N; Sazonova Y; Varetska O; Altice FL; Saliuk T; Vickerman P
J Int AIDS Soc; 2023 Apr; 26(4):e26073. PubMed ID: 37012669
[TBL] [Abstract][Full Text] [Related]
17. HIV/HCV co-infection and associated risk factors among injecting drug users in Dar es Salaam, Tanzania: potential for HCV elimination.
Leyna GH; Makyao N; Mwijage A; Ramadhan A; Likindikoki S; Mizinduko M; Leshabari MT; Moen K; Mmbaga EJ
Harm Reduct J; 2019 Dec; 16(1):68. PubMed ID: 31829199
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of strategies to improve HCV screening, linkage-to-care and treatment in remand prison settings in England.
Mohamed Z; Scott N; Al-Kurdi D; Selvapatt N; Thursz MR; Lemoine M; Brown AS; Nayagam S
Liver Int; 2020 Dec; 40(12):2950-2960. PubMed ID: 32750192
[TBL] [Abstract][Full Text] [Related]
19. Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol.
Klaman SL; Godino JG; Northrup A; Lewis SV; Tam A; Carrillo C; Lewis R; Matthews E; Mendez B; Reyes L; Rojas S; Ramers C
BMC Infect Dis; 2024 Jan; 24(1):105. PubMed ID: 38238686
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands.
Helsper CW; Janssen MP; van Essen GA; Croes EA; van der Veen C; de Wit AG; de Wit NJ
Int J Drug Policy; 2017 Sep; 47():117-125. PubMed ID: 28826994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
